1 year ago

Work programme 2017


assessment. Emerging new

assessment. Emerging new technologies, personalised medicines, new advanced therapies, combination and borderline products all contribute to the increasing complexity of medicines. The availability of sustainable, high-quality scientific and regulatory expertise will be a critical success factor in addressing the progress in regulatory science. Therefore, strengthening capacity and capability development across the network through the aforementioned Network Training Centre, supporting the work of the innovation network, and enriching expertise through outreach to academia will remain an important part of the Agency's agenda. At the same time, the face of the pharmaceutical industry is evolving, with a high number of small or medium-sized enterprises (SMEs) as well as academia undertaking the early stages of medicines development. Recent initiatives have reinforced the regulatory support on offer to medicines developers. There is a constant need for continuous improvement of our processes and approaches to ensure that prospective medicines reach their patients in such an environment. Timely access to promising medicines The ever-increasing expectations of patients, animal owners and healthcare professionals to have promising medicines available at the earliest appropriate opportunity, in combination with the continuous need for flexible and fast reaction to arising public-health threats (many zoonotic), requires exploring flexible licencing pathways and a lifespan approach to medicines. The Agency launched its PRIME scheme in 2016, providing early and reinforced regulatory and scientific advice to priority medicines, and is committed to working in collaboration with the European Commission and the STAMP expert group on the development and implementation of tools to further improve timely access to medicines for patients. Maintaining the quality of scientific assessment and ensuring the safety of medicines remains paramount, and introducing a more comprehensive approach to planning and generation of postauthorisation data is an important component in these efforts. Collaboration with HTA bodies and payer organisations as downstream decision-makers will further increase, and contribute towards treatment options becoming available to patients. This concerns all phases of the life-cycle, from horizon scanning, through planning for data generation, at the market entry phase and during post-authorisation evidence generation. Continuation of scientific and technical cooperation with EUnetHTA Joint Action 3, which runs from 2016 to 2020, particularly through the deliverables of the relevant work packages, is envisaged. The availability of veterinary medicines in general, and in particular vaccines against emerging infectious animal disease with relevance for human health or which are of major economic significance in terms of animal production, is of concern. To facilitate the availability of veterinary medicines, the Agency will pursue a number of initiatives detailed in this programming document that fall within its own mandate and will, at the same time, work closely with the Network to deliver shared initiatives with this objective, such as the HMA/EMA Task Force on Availability and the Action Plan on Availability of Veterinary Vaccines. Enhancing international cooperation The globalisation of pharmaceutical activities results in an increasing number of manufacturing and clinical-trial activities being conducted outside the EU. This, coupled with the complexity of international supply chains, presents challenges to ensure adherence to the required clinical-trial and manufacturing standards, to ensure data integrity, and to manage the risks of supply chain and counterfeit operations. Work programme 2017 EMA/583016/2016 Page 8/123

To ensure that medicines tested and manufactured outside the EU meet the EU requirements, the Agency and NCAs will continue and strengthen their collaboration with international partners in relation to work-sharing and collaborative inspections, information exchanges and greater mutual reliance, as well as harmonisation of standards and building regulatory capacity, especially in countries where manufacturing and clinical trials take place. With regard to standards in veterinary medicines, a particular focus will be on fostering the VICH Outreach programme, which aims to extend uptake of VICH guidelines to countries with less developed regulatory systems. In the global arena, regulators worldwide are also increasingly recognising the potential and need to create synergies, avoid duplications and use global regulatory resources more effectively. Here, the Agency continues its collaboration with non-EU competent authorities and regulators to increase worksharing in various domains, and reliance on each other's inspection and assessment activities, develop exchanges of information on products throughout their lifecycle, cooperate on activities in particular areas of interest, and build capacity and capability of regulators in candidate and potential candidate countries,as well as countries with less developed systems (including through the Network Training Centre). Work to optimise use of Article 58 of Regulation EC (No) 726/2004 remains an important item on the Agency's agenda. Addressing public-health priorities Antimicrobial resistance (AMR) is a global health crisis, as recognised by the development of a Global Action Plan for AMR by the World Health Organization (WHO). The Food and Agriculture Organisation of the United Nations and the World Organisation for Animal Health (OIE) have also created similar, related plans in terms of their strategy on AMR and prudent use of antimicrobials. Efforts to combat AMR will remain high on the Agency's agenda and will include providing the necessary support to the European Commission Action Plan on AMR, to the Transatlantic Task Force on Antimicrobial Resistance (TATFAR) as well as to the WHO, OIE and other international initiatives. The Agency will continue to cooperate closely with other EU institutions, particularly ECDC and EFSA, adopting the 'One Health' approach. The approach will encompass developing or updating relevant guidelines (including paediatric aspects), and balancing the need to assure the continued availability of antimicrobials in veterinary medicines with the need to minimise the risk to man from their use in animals whilst contributing to effort to develop alternative approaches to the use of such medicines in managing infectious disease in animals. Alongside known problems such as antimicrobial resistance, new diseases and issues emerge that need addressing. Societal trends, including an aging population, polypharmacy and comorbidity, and new and redefined diseases such as dementia, will become more of a public-health burden. The Agency will implement its geriatric strategy and engage in a number of activities related to dementia and Alzheimer's disease. The Agency will also continue its work to facilitate the development of medicines for rare diseases and identify areas in need of further research. To address shortages and ensure availability of authorised medicines, the Agency will continue promoting proactive risk-management by manufacturers and marketing-authorisation holders, and instil controls to ensure product quality and supply continuity. Since the availability of medicines goes beyond supply issues, the Agency will also support additional measures that can address the wider aspects of availability using existing fora with NCAs. The Agency will also be improving its public-health crisis-response mechanisms, building on the past experience of pandemic influenza and the work on Ebola and Zika. Veterinary medicines Work programme 2017 EMA/583016/2016 Page 9/123

2017 Work Programme
MHRA powerpoint template - TOPRA
ANNUAL REPORT - Bundesverband für Tiergesundheit
Work Programme 2013 - ECHA - Europa
Work Programme 2011 - ERA - Europa
DIA European Regulatory Affairs Forum 2010 - SwAPP
Programme (pdf)
Nanoforum - Nanotech Regulatory Document Archive
Educational Evaluation in Youth Work - EU-CoE youth partnership
VMGN 11 - Veterinary Medicines Directorate - Defra
Download this publication - The Stockholm Network